Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
NOE-101 (basimglurant), a highly selective, potent, and cell-penetrant negative allosteric modulator of mGlu5 receptors for the management of pain associated with TN.
Lead Product(s): Basimglurant
Therapeutic Area: Neurology Product Name: NOE-101
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
Addex intends to use the net proceeds from this offering to advance its clinical and preclinical pipeline including development and commercialization of its lead asset ADX48621(dipraglurant).
Lead Product(s): Dipraglurant
Therapeutic Area: Neurology Product Name: ADX48621
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Armistice Master Fund Ltd.
Deal Size: $4.2 million Upfront Cash: Undisclosed
Deal Type: Financing July 26, 2022
Details:
Addex intends to use the net proceeds from this offering to advance its clinical and preclinical pipeline including development and commercialization of its lead asset ADX48621(dipraglurant).
Lead Product(s): Dipraglurant
Therapeutic Area: Neurology Product Name: ADX48621
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Armistice Master Fund LTV
Deal Size: $4.2 million Upfront Cash: Undisclosed
Deal Type: Financing July 22, 2022
Details:
ADX48621 (Dipraglurant (Immediate Release), as a novel orally available mGlu5 NAM, for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).
Lead Product(s): Dipraglurant
Therapeutic Area: Neurology Product Name: ADX48621
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2022
Details:
Gantenerumab, did not meet its primary endpoint in people who have an early-onset, inherited form of Alzheimer’s disease.
Lead Product(s): Gantenerumab
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2020
Details:
Risdiplam demonstrated statistically significant and medically meaningful motor milestone improvement in infants with Type 1 SMA
Lead Product(s): Risdiplam
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2020
